✦ LIBER ✦

Early decline of the HCV core antigen can predict SVR in patients with HCV treated by Pegylated interferon plus ribavirin combination therapy

✍ Scribed by Tatsuya FUJINO; Makoto NAKAMUTA; Yoko AOYAGI; Kunitaka FUKUIZUMI; Ryosuke TAKEMOTO; Tsuyoshi YOSHIMOTO; Toshihiko MIYAHARA; Naohiko HARADA; Hironori SAKAI; Manabu NAKASHIMA; Munechika ENJOJI

Book ID: 111414418
Publisher: Wiley (Blackwell Publishing)
Year: 2009
Tongue: English
Weight: 118 KB
Volume: 10
Category: Article
ISSN: 1751-2972
DOI: 10.1111/j.1751-2980.2008.00358.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Ortho total HCV core antigen assay can a

Ortho total HCV core antigen assay can aid early prediction of response in patients treated with interferon/ribavirin

✍ Francoise Lunel; Pascal Veillon; Christopher Payan 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 112 KB

546 Early HCV-RNA decline in peripheral

546 Early HCV-RNA decline in peripheral blood mononuclear cells predicts SVR versus relapse in chronic hepatitis C patients treated with pegylated interferon-α plus ribavirin

✍ P. Pugnale; A.U. Neumanne; J.-M. Pawlotsky; S. Zeuzem; F. Negro 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 131 KB

Early decline of hemoglobin can predict

Early decline of hemoglobin can predict progression of hemolytic anemia during pegylated interferon and ribavirin combination therapy in patients with chronic hepatitis C

✍ Naoki Hiramatsu; Nao Kurashige; Tsugiko Oze; Tetsuo Takehara; Shinji Tamura; Aki 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 237 KB

[589] SVR RATES ARE IMPACTED BY RVR/EVR

[589] SVR RATES ARE IMPACTED BY RVR/EVR AND FIBROSIS SCORE IN PATIENTS TREATED WITH TARIBAVIRIN IN COMBINATION WITH PEGYLATED INTERFERON ALFA-2a FOR THE TREATMENT OF HCV

✍ S. Flamm; M. Rodriguez-Torres; M. Silva; Y. Li; B. Murphy 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 138 KB

A 3-ARM randomized study evaluating the

A 3-ARM randomized study evaluating the efficacy of triple therapy of pegylated or recombinant interferon alpha-2a 3 MU both combined with ribavirin and amantadine versus dual therapy of recombinant interferon alpha-2a plus ribavirin in naive patients with chronic HCV hepatitis

✍ Alessandra Mangia; Giovanni Ricci; Nicola Minerva; Marcello Persico; Vito Carret 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 100 KB